UnitedHealthcare says it’s dropping some of its Medicare Advantage plans that collectively cover 600,000 people.

In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...

The Trump administration is planning to pilot covering weight loss drugs. A longtime healthcare exec moves to a strategic advisory role at General Catalyst.

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Trump administration eyes Medicare and Medicaid coverage for weight loss drugs like Wegovy and Ozempic in a five-year pilot ...

The stock of Eli Lilly and Company was up in early trading on Aug. 4 amid reports that Medicare may soon cover its weight-loss medications. This could significantly boost the affordability of Eli ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

Washington Post National Health Reporter Paige Winfield Cunningham joins Michael Smerconish to discuss how the Trump administration is considering expanding healthcare coverage for weight loss drugs.